Agile Therapeutics, Inc.
Agile Therapeutics, Inc. (AGRX) Stock Overview
Explore Agile Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
10.4M
P/E Ratio
-0.23
EPS (TTM)
$-1.70
ROE
1.32%
AGRX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Agile Therapeutics, Inc. (AGRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $268.67.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.23 and a market capitalization of 10.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.